Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.69 USD

27.69
1,056,559

-0.49 (-1.74%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers

Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers

    Bet on These 5 GARP Stocks Based on Low PEG Ratio

    A lower PEG ratio, preferably less than 1, is always better for GARP investors.

      Company News For Nov 10, 2017

      Companies in the News are: ROKU,M,SEDG,PRGO

        Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up

        Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.

          Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

          Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

            4 Medical Product Stocks Likely to Top Q3 Earnings Estimates

            The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.

              Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick

              Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.

                Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval

                Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.

                  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant

                  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant

                    Company News For August 11, 2017

                    Companies in the new are: PRGO,KSS,EAT,LYV

                      Arpita Dutt headshot

                      Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure

                      This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.

                        Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

                        Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

                          Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?

                          Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.

                            Arpita Dutt headshot

                            Generic Drug Stocks Take a Hit: Here's Why

                            As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.

                              Perrigo Company Gets FDA Approval for Generic Topical Gel

                              Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                                Why Is Perrigo (PRGO) Up 5% Since the Last Earnings Report?

                                Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Company News for June 01, 2017

                                  Companies in the News are: KORS,ADI,PRGO,JILL

                                    Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact

                                    Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.

                                      Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

                                      Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

                                        Arpita Dutt headshot

                                        Generic Drugmakers Tumble as Perrigo Discloses DoJ Search

                                        With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.

                                          Perrigo Launches First to Market OTC Equivalent of Rogaine

                                          Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).

                                            Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View

                                            The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.

                                              Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

                                              Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

                                                Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

                                                Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.

                                                  Is Perrigo Company (PRGO) a Great Stock for Value Investors?

                                                  Let's delve into the value metrics of Perrigo Company (PRGO) and determine whether it is a good value investment right now.